Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,141 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 308 · Balance 25,141 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
Section 16 reporting ended · disclosed 2021-01-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-01-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-12-28 · Gift · Disposed 500 · Balance 380,467 Row 2 · 2021-01-26 · Other · Disposed 380,467 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-26 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
F2: The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2019 Filed Jul 17, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 15,000 | $40.04 | $600,561.00 |
DisclosureSEC source: 0000899243-19-019765 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 501,527 F2 · price: Represents the weighted average sale price of the shares ranging from $39.67 to $40.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| May 31, 2019 Filed Jul 17, 2019 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,769 | $12.01 | $21,246.57 |
DisclosureSEC source: 0000899243-19-019765 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,850 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 30, 2019 Filed May 31, 2019 16:17 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $32.64 | $163,178.50 |
DisclosureSEC source: 0000899243-19-015285 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 516,527 F1 · price: Represents the weighted average sale price of the shares sold ranging from $32.63 to $32.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C. Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| May 03, 2019 Filed May 6, 2019 20:37 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $25.03 | $125,150.00 |
DisclosureSEC source: 0000899243-19-012357 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 521,527 F1 · price: Represents the weighted average sale price of the shares sold ranging from $25.02 to $25.18 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The shares are held by Jonathan C Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,892 | $25.30 | $98,467.60 |
DisclosureSEC source: 0000899243-19-012105 · doc4.xml · nonDerivative · entry 3 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 526,527 F2 · ownership.nature: The shares are held by Jonathan C Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| May 01, 2019 Filed May 3, 2019 21:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,108 | $26.01 | $28,819.08 |
DisclosureSEC source: 0000899243-19-012105 · doc4.xml · nonDerivative · entry 2 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 530,419 F2 · ownership.nature: The shares are held by Jonathan C Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| April 15, 2019 Filed Apr 16, 2019 21:10 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,000 | $23.11 | $115,550.00 |
DisclosureSEC source: 0000899243-19-010707 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 531,527 F1 · ownership.nature: The shares are held by Jonathan C Fox and Suzanne Markel-Fox, Co-Trustees of the Fox Family Trust Dated 17 Dec 2014. Read SEC document |
| November 30, 2018 Filed May 3, 2019 21:52 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 1,081 | $12.01 | $12,982.81 |
DisclosureSEC source: 0000899243-19-012105 · doc4.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 19:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0000899243-18-028484 · doc4.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 70,000 stock options (the "Grant") on November 5, 2018. The shares subject to the Grant shall vest as follows: one quarter of the shares shall vest on November 5, 2019 and the remaining unvested shares shall vest ratably over the following 36 months, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.